EU/US Properties Organoleptics Cosmetics Suppliers Safety Safety in use Safety references References Other Blenders Uses Occurrence Synonyms Articles Notes
 

tafluprost
isopropyl (5Z)-7-{(1R,2R,3R,5S)-2-((1E)-3,3-difluoro-4-phenoxybut-1- enyl)-3,5-dihydroxycyclopentyl}hept-5-enoate

Supplier Sponsors

Name:propan-2-yl (Z)-7-[(1R,2R,3R,5S)-2-[(E)-3,3-difluoro-4-phenoxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate
CAS Number: 209860-87-7Picture of molecule3D/inchi
FDA UNII: 1O6WQ6T7G3
Nikkaji Web:J1.975.790K
XlogP3-AA:4.50 (est)
Molecular Weight:452.53878640
Formula:C25 H34 F2 O5
NMR Predictor:Predict (works with chrome, Edge or firefox)
Category:cosmetic ingredient for hair conditioning
 
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Google Scholar:Search
Google Books:Search
Google Scholar: with word "volatile"Search
Google Scholar: with word "flavor"Search
Google Scholar: with word "odor"Search
Google Patents:Search
US Patents:Search
EU Patents:Search
Pubchem Patents:Search
PubMed:Search
NCBI:Search
 
Physical Properties:
Assay: 95.00 to 100.00
Food Chemicals Codex Listed: No
Soluble in:
 water, 0.003928 mg/L @ 25 °C (est)
 
Organoleptic Properties:
Odor and/or flavor descriptions from others (if found).
 
Cosmetic Information:
CosIng:cosmetic data
Cosmetic Uses: hair conditioning
 
Suppliers:
BOC Sciences
For experimental / research use only.
Tafluprost 0.98
Odor: characteristic
Use: Tafluprost is a novel prostanoid used in the treatment of glaucoma and is the first prostanoid to be released in a preservative free-formula.
 
Safety Information:
 
Hazards identification
 
Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
None found.
GHS Label elements, including precautionary statements
 
Pictogram
 
Hazard statement(s)
None found.
Precautionary statement(s)
None found.
Oral/Parenteral Toxicity:
Not determined
Dermal Toxicity:
Not determined
Inhalation Toxicity:
Not determined
 
Safety in Use Information:
Category:
cosmetic ingredient for hair conditioning
Recommendation for tafluprost usage levels up to:
 not for fragrance use.
 
Recommendation for tafluprost flavor usage levels up to:
 not for flavor use.
 
Safety References:
EPI System: View
ClinicalTrials.gov:search
Daily Med:search
AIDS Citations:Search
Cancer Citations:Search
Toxicology Citations:Search
EPA ACToR:Toxicology Data
EPA Substance Registry Services (SRS):Registry
Laboratory Chemical Safety Summary :9868491
National Institute of Allergy and Infectious Diseases:Data
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-2-[(E)-3,3-difluoro-4-phenoxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate
Chemidplus:0209860877
 
References:
 propan-2-yl (Z)-7-[(1R,2R,3R,5S)-2-[(E)-3,3-difluoro-4-phenoxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate
NIST Chemistry WebBook:Search Inchi
Pubchem (cid):9868491
Pubchem (sid):135262832
 
Other Information:
(IUPAC):Atomic Weights of the Elements 2011 (pdf)
Videos:The Periodic Table of Videos
tgsc:Atomic Weights use for this web site
(IUPAC):Periodic Table of the Elements
CHEBI:View
CHEMBL:View
KEGG (GenomeNet):D06274
HMDB (The Human Metabolome Database):Search
ChemSpider:View
Wikipedia:View
 
Potential Blenders and core components note
None Found
 
Potential Uses:
None Found
 
Occurrence (nature, food, other):note
 not found in nature
 
Synonyms:
5-heptenoic acid, 7-((1R,2R,3R,5S)-2-((1E)-3,3-difluoro-4-phenoxy-1-buten-1-yl)-3,5- dihydroxycyclopentyl)-, 1-methylethyl ester, (5Z)-
1-methylethyl (5Z)-7-{(1R,2R,3R,5S)-2-((1E)-3,3-difluoro-4-phenoxybut-1-enyl)-3,5- dihydroxycyclopentyl}hept-5-enoate
 propan-2-yl (Z)-7-[(1R,2R,3R,5S)-2-[(E)-3,3-difluoro-4-phenoxybut-1-enyl]-3,5-dihydroxycyclopentyl]hept-5-enoate
isopropyl (5Z)-7-{(1R,2R,3R,5S)-2-((1E)-3,3-difluoro-4-phenoxybut-1- enyl)-3,5-dihydroxycyclopentyl}hept-5-enoate
 

Articles:

PubMed:Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost.
PubMed:The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study.
PubMed:Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study.
PubMed:Effects of pre-surgical administration of prostaglandin analogs on the outcome of trabeculectomy.
PubMed:[Assessing the added benefit of new ophthalmic drugs : Which additional insights can be extracted from the early benefit assessment?]
PubMed:Retinal Blood Flow Velocity Change in Parafoveal Capillary after Topical Tafluprost Treatment in Eyes with Primary Open-angle Glaucoma.
PubMed:Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study.
PubMed:Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Effectiveness and Treatment Persistence.
PubMed:Blood Pressure Elevation Associated with Topical Prostaglandin F2α Analogs: An Analysis of the Different Spontaneous Adverse Event Report Databases.
PubMed:Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study.
PubMed:A Novel Convergent Synthesis of the Potent Antiglaucoma Agent Tafluprost.
PubMed:Fixed combination of travoprost and timolol maleate reduces intraocular pressure in Japanese patients with primary open-angle glaucoma or ocular hypertension: analysis by prostaglandin analogue.
PubMed:Impact of prostaglandin glaucoma drops on platelet-activating factor action: an in vitro study.
PubMed:24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy.
PubMed:Analysis of the effects of preservative-free tafluprost on the tear proteome.
PubMed:Rh(I)-Catalyzed 1,4-Conjugate Addition of Alkenylboronic Acids to a Cyclopentenone Useful for the Synthesis of Prostaglandins.
PubMed:Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma.
PubMed:Prospective Observational Post-marketing Study of Tafluprost 0.0015%/Timolol 0.5% Combination Ophthalmic Solution for Glaucoma and Ocular Hypertension: Short-Term Efficacy and Safety.
PubMed:Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination.
PubMed:Ocular Tolerability of Preservative-Free Tafluprost and Latanoprost: in vitro and in vivo Comparative Study.
PubMed:Preservative-free tafluprost in the treatment of open-angle glaucoma or ocular hypertension in India: a phase III clinical trial.
PubMed:Long-term topical application of preservative-free prostaglandin analogues evokes macrophage infiltration in the ocular adnexa.
PubMed:Long-term assessment of prostaglandin analogs and timolol fixed combinations vs prostaglandin analogs monotherapy.
PubMed:Development of Novel RP-HPLC Method for Separation and Estimation of Critical Geometric Isomer and Other Related Impurities of Tafluprost Drug Substance and Identification of Major Degradation Compounds by Using LC-MS.
PubMed:Tafluprost Ophthalmic Solution 0.0015 %: A Review in Glaucoma and Ocular Hypertension.
PubMed:Preservative-free tafluprost/timolol fixed combination: a new opportunity in the treatment of glaucoma.
PubMed:Pediatric Glaucoma: Pharmacotherapeutic Options.
PubMed:Prostaglandins in the eye: Function, expression, and roles in glaucoma.
PubMed:Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials.
PubMed:Bimatoprost, latanoprost, and tafluprost induce differential expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases.
PubMed:Association between glaucoma eye drops and hyperemia.
PubMed:Effects of prostaglandin analogs on blood flow velocity and resistance in the ophthalmic artery of rabbits.
PubMed:Effect of preservative-free tafluprost on intraocular pressure, pupil diameter, and anterior segment structures in normal canine eyes.
PubMed:New drugs and preparations for open-angle glaucoma in adults.
PubMed:Nonresponders to Prostaglandin Analogs Among Normal-Tension Glaucoma Patients.
PubMed:Comparison of Ocular Pulse Amplitude Lowering Effects of Preservative-Free Tafluprost and Preservative-Free Dorzolamide-Timolol Fixed Combination Eyedrops.
PubMed:Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.
PubMed:Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension.
PubMed:Fixed Combination of Travoprost and Timolol Maleate Reduces Intraocular Pressure in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Prospective Multicenter Open-Label Study.
PubMed:Twenty-four-hour efficacy of preservative-free tafluprost for open-angle glaucoma patients, assessed by home intraocular pressure (Icare-ONE) and blood-pressure monitoring.
PubMed:Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies.
PubMed:Comparison of Ocular Pulse Amplitude-Lowering Effects of Tafluprost and Latanoprost by Dynamic Contour Tonometry.
PubMed:Benefits of Tafluprost and Timolol Fixed-Dose Combination for the Treatment of Glaucoma Are Confirmed by Studies on Experimental Animal Models.
PubMed:In Vivo Effects of Preservative-free and Preserved Prostaglandin Analogs: Mouse Ocular Surface Study.
PubMed:In vitro Effects of Prostaglandin Analogs on Cultured Astrocytes Obtained from the Lamina Cribrosa.
PubMed:The Impact of Glaucoma Medications on Corneal Wound Healing.
PubMed:Effects of Four Formulations of Prostaglandin Analogs on Eye Surface Cells. A Comparative Study.
PubMed:[Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)].
PubMed:A 1-year randomized study of the clinical and confocal effects of tafluprost and latanoprost in newly diagnosed glaucoma patients.
PubMed:[Tafluprost--a novel prostaglandin F2alpha analogue].
PubMed:Comparison of the toxicity profile of benzalkonium chloride-preserved tafluprost and SofZia-preserved travoprost applied to the ocular surface.
PubMed:Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma.
PubMed:Excipients of preservative-free latanoprost induced inflammatory response and cytotoxicity in immortalized human HCE-2 corneal epithelial cells.
PubMed:A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components.
PubMed:Latanoprost in the treatment of glaucoma.
PubMed:The circadian changes of intraocular pressure and ocular perfusion pressure after tafluprost compared with travoprost in normal tension glaucoma.
PubMed:Intraocular pressure decrease with preservative-free fixed and unfixed combination of tafluprost and timolol in pseudoexfoliative glaucoma.
PubMed:Comparison of the ocular surface changes following the use of two different prostaglandin F2α analogues containing benzalkonium chloride or polyquad in rabbit eyes.
PubMed:Efficacy of preservative-free tafluprost in patients with normal-tension glaucoma previously treated with latanoprost.
PubMed:Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products.
PubMed:Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension.
PubMed:Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma.
PubMed:Efficacy of intravitreal dexamethasone implant for prostaglandin-induced refractory pseudophakic cystoid macular edema: case report and review of the literature.
PubMed:Mechanisms of benzalkonium chloride toxicity in a human trabecular meshwork cell line and the protective role of preservative-free tafluprost.
PubMed:Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredients.
PubMed:Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety.
PubMed:Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions.
PubMed:Ocular surface cytotoxicity and safety evaluation of tafluprost, a recently developed anti-glaucoma prostaglandin analog.
PubMed:Activation of the prostanoid FP receptor inhibits adipogenesis leading to deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy.
PubMed:OCT evaluation of neuroprotective effects of tafluprost on retinal injury after intravitreal injection of endothelin-1 in the rat eye.
PubMed:Incidence of deepening of the upper eyelid sulcus on treatment with a tafluprost ophthalmic solution.
PubMed:Efficacy and tolerability of preservative-free tafluprost 0.0015% in Korean patients with glaucoma.
PubMed:In vitro effects of preservative-free and preserved prostaglandin analogs on primary cultured human conjunctival fibroblast cells.
PubMed:Safety and Efficacy of Benzalkonium Chloride-optimized Tafluprost in Japanese Glaucoma Patients With Existing Superficial Punctate Keratitis.
PubMed:Urrets- Zavalia Syndrome after glaucoma filtration device implantation.
PubMed:Eyelash growth induced by topical prostaglandin analogues, bimatoprost, tafluprost, travoprost, and latanoprost in rabbits.
PubMed:Effect of preservative-free tafluprost on keratocytes, sub-basal nerves, and endothelium: a single-blind one-year confocal study on naïve or treated glaucoma and hypertensive patients versus a control group.
PubMed:Subtenon triamcinolone injection for postoperative cystoid macular edema associated with tafluprost.
PubMed:Incidence of deepening of upper eyelid sulcus after topical use of tafluprost ophthalmic solution in Japanese patients.
PubMed:Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted Indirect comparison meta-analysis of randomized clinical trials.
PubMed:Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma.
PubMed:A study of the association between patterns of eye drop prescription and medication usage in glaucoma subjects.
PubMed:[Tafluprost (Saflutan) ophthalmic use].
PubMed:Equilibrium binding interactions between lotrafilcon a soft contact lenses and the two prostaglandin antiglaucoma drugs bimatoprost and tafluprost.
PubMed:Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension.
PubMed:Effect of tafluprost 0.0015% on central corneal thickness in patients with primary open-angle glaucoma.
PubMed:Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension.
PubMed:Short- and long-term corneal vascular effects of tafluprost eye drops.
PubMed:Conjunctival goblet cells density and preservative-free tafluprost therapy for glaucoma: an in vivo confocal microscopy and impression cytology study.
PubMed:Effect of topical tafluprost on optic nerve head blood flow in patients with myopic disc type.
PubMed:New drug update: 2012.
PubMed:Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations.
PubMed:Tear clearance and ocular symptoms in patients treated with preservative-free prostaglandins.
PubMed:Therapeutic uses of prostaglandin F(2α) analogues in ocular disease and novel synthetic strategies.
PubMed:New drugs 2013, Part I.
PubMed:Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma.
PubMed:[Efficacy and tolerability of preservative-free tafluprost 0.0015 % in the treatment of glaucoma and ocular hypertension].
PubMed:Tafluprost: the first preservative-free prostaglandin to treat open-angle glaucoma and ocular hypertension.
PubMed:Acute effects of glaucoma medications and benzalkonium chloride on pre-adipocyte proliferation and adipocyte cytotoxicity in vitro.
PubMed:Corneal epithelial cell viability following exposure to ophthalmic solutions containing preservatives and/or antihypertensive agents.
PubMed:A randomized crossover study comparing tafluprost 0.0015% with travoprost 0.004% in patients with normal-tension glaucoma [corrected].
PubMed:The effects of prostaglandin analogues on intracellular Ca2+ in ciliary arteries of wild-type and prostanoid receptor-deficient mice.
PubMed:Adverse periocular reactions to five types of prostaglandin analogs.
PubMed:Cell viability score as an integrated indicator for cytotoxicity of benzalkonium chloride-containing antiglaucoma eyedrops.
PubMed:Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs.
PubMed:Effects of AFP-172 on COX-2-induced angiogenic activities on human umbilical vein endothelial cells.
PubMed:Clobazam, ezogabine, and tafluprost.
PubMed:Toxicity evaluation of antiglaucoma drugs using stratified human cultivated corneal epithelial sheets.
PubMed:Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month, single-blind, observational study on naïve ocular hypertension or glaucoma patients.
PubMed:Comparison of efficacy of four prostaglandin analogues by bilateral treatment in healthy subjects.
PubMed:Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma.
PubMed:A prospective study evaluating IOP changes after switching from a therapy with prostaglandin eye drops containing preservatives to nonpreserved tafluprost in glaucoma patients.
PubMed:Drug metabolite heterogeneity in cultured single cells profiled by pico-trapping direct mass spectrometry.
PubMed:Tafluprost (Zioptan) - a new topical prostaglandin for glaucoma.
PubMed:Conjunctiva-associated lymphoid tissue (CALT) reactions to antiglaucoma prostaglandins with or without BAK-preservative in rabbit acute toxicity study.
PubMed:Spanish multicenter tafluprost tolerability study.
PubMed:FDA approves glaucoma treatment.
PubMed:Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.
PubMed:Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma.
PubMed:In vitro study of antiadipogenic profile of latanoprost, travoprost, bimatoprost, and tafluprost in human orbital preadiopocytes.
PubMed:The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo.
PubMed:Tafluprost for glaucoma.
PubMed:Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin-timolol fixed combinations in primary open-angle glaucoma.
PubMed:Efficacy and safety of tafluprost in normal-tension glaucoma with intraocular pressure of 16 mmHg or less.
PubMed:Tafluprost: a novel prostaglandin analog for treatment of glaucoma.
PubMed:Neuroprotective effects of prostaglandin analogues on retinal ganglion cell death independent of intraocular pressure reduction.
PubMed:Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension.
PubMed:Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost.
PubMed:Metabolism and ocular tissue distribution of an antiglaucoma prostanoid, tafluprost, after ocular instillation to monkeys.
PubMed:Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system.
PubMed:Ocular hypotensive effect of tafluprost in latanoprost low-responder cynomolgus monkeys.
PubMed:Use of an adult rat retinal explant model for screening of potential retinal ganglion cell neuroprotective therapies.
PubMed:Gateways to clinical trials.
PubMed:Tafluprost for the reduction of interocular pressure in open angle glaucoma and ocular hypertension.
PubMed:Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension.
PubMed:Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension.
PubMed:Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells.
PubMed:Effects of prostaglandin F(2α) analogues on endothelin-1-induced impairment of rabbit ocular blood flow: comparison among tafluprost, travoprost, and latanoprost.
PubMed:Cytotoxicity of prostaglandin analog eye drops preserved with benzalkonium chloride in multiple corneoconjunctival cell lines.
PubMed:Twenty-four-hour ocular hypotensive effects of 0.0015% tafluprost and 0.005% latanoprost in healthy subjects.
PubMed:A review of preserved and preservative-free prostaglandin analogues for the treatment of open-angle glaucoma and ocular hypertension.
PubMed:In vitro toxicity of topical ocular prostaglandin analogs and preservatives on corneal epithelial cells.
PubMed:IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
PubMed:Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
PubMed:[Intraocular pressure lowering effect of 0.0015% tafluprost as compared to placebo in patients with normal tension glaucoma: randomized, double-blind, multicenter, phase III study].
PubMed:[Optimization of benzalkonium chloride concentration in 0.0015% tafluprost ophthalmic solution from the points of ocular surface safety and preservative efficacy].
PubMed:Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.
PubMed:Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension.
PubMed:Effects of topical phenylephrine and tafluprost on optic nerve head circulation in monkeys with unilateral experimental glaucoma.
PubMed:Effects of repeated administrations of tafluprost, latanoprost, and travoprost on optic nerve head blood flow in conscious normal rabbits.
PubMed:A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost.
PubMed:[New developments in glaucoma medical treatment].
PubMed:Ocular hypotensive effects of anti-glaucoma agents in mice.
PubMed:[Receptors involved in the mechanism of action of topical prostaglandines].
PubMed:Tafluprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo.
PubMed:Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats.
PubMed:Gateways to clinical trials.
PubMed:Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma.
PubMed:[Glaucoma--strategy of treatment].
PubMed:Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost.
PubMed:Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis.
PubMed:Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers.
PubMed:In search of improved prostaglandin treatment for glaucoma.
PubMed:Short-term effects of topical tafluprost on retinal blood flow in cats.
PubMed:Tafluprost, a new potent prostanoid receptor agonist: a dose-response study on pharmacodynamics and tolerability in healthy volunteers.
PubMed:Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride.
PubMed:Relaxing effect and mechanism of tafluprost on isolated rabbit ciliary arteries.
PubMed:In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line.
PubMed:A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males.
PubMed:The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice.
PubMed:Prostanoids in the therapy of glaucoma.
PubMed:Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation.
PubMed:Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug.
PubMed:New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents.
 
Notes:
None found
Please share your Comments.
Email Address:
Top of Page Home
Copyright © 1980-2021 The Good Scents Company (tgsc) ™ Disclaimer Privacy Policy